Raziel Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Raziel Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Raziel Therapeutics: 9 sponsored US clinical trials, none currently recruiting.

Raziel Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dercum's Disease Lipomas, with 1 trials.

Top-decile sponsor footprint

Raziel Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 2

An Open-label Study That Will Test a Second Treatment Session of RZL-012.

NCT05763160
COMPLETED Phase 1

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

NCT05476679
COMPLETED Phase 1

An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.

NCT05466448
COMPLETED Phase 2

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

NCT05445557
COMPLETED Phase 2

Efficacy and Safety of RZL-012 on Submental Fat Reduction

NCT04867434
COMPLETED Phase 2

RZL-012 for Dercum's Disease Lipomas

NCT04229030
COMPLETED Phase 2

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

NCT04086823
COMPLETED Phase 2

Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease

NCT03492840
COMPLETED Phase 2

Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers

NCT03171415

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 7

Therapeutic Areas

Dercum's Disease Lipomas 1
Submental Fat 1
Weight Loss 1
Obesity 1
Overweight and Obesity 1

How the Raziel Therapeutics early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 9 completed (100%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Dercum's Disease Lipomas (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Raziel Therapeutics: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Raziel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Raziel Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Raziel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Raziel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Raziel Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Raziel Therapeutics or any single study.

  • None of Raziel Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Dercum's Disease Lipomas is the condition Raziel Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dercum's Disease Lipomas trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Raziel Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.